Copyright
©The Author(s) 2018.
World J Gastroenterol. Dec 14, 2018; 24(46): 5288-5296
Published online Dec 14, 2018. doi: 10.3748/wjg.v24.i46.5288
Published online Dec 14, 2018. doi: 10.3748/wjg.v24.i46.5288
Figure 1 Loss of efficacy at 12 mo in both groups.
- Citation: Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296
- URL: https://www.wjgnet.com/1007-9327/full/v24/i46/5288.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i46.5288